1286
N. V. Lakshmi et al. / Tetrahedron Letters 53 (2012) 1282–1286
CN
N
NC
CN
NC
HN
H2N
NC
NC
R1
N
N
NC
NC
O
O
N
R
R1
N
CN
H2N
NEt3
14a-h
H
+
O
ethanol, reflux
NC
N
CN
N
R
1
2
3
rac- 15a-h
Scheme 7. Synthesis of spiro-oxindoles containing spiropiperidine ring derivatives 15a–h.
3. (a) Basavaiah, D.; Reddy, R. K. Org. Lett. 2007, 9, 57; (b) Kumar, R. R.; Perumal,
S.; Senthilkumar, P.; Yogeeswari, P.; Sriram, D. Eur. J. Med. Chem. 2009, 44,
3821; (c) Badillo, J. J.; Arevalo, G. E.; Fettinger, J. C.; Franz, A. K. Org. Lett. 2011,
13, 418; (d) Lu, C.; Xiao, Q.; Floreancig, P. E. Org. Lett. 2010, 12, 5112; (e) Cheng,
M. –N.; Wang, H.; Gong, L. –Z. Org. Lett. 2011, 13, 2418.
4. (a) Hilton, S. T.; Ho, T. C. T.; Pljevaljcic, G.; Jones, K. Org. Lett. 2000, 2, 2639; (b)
Babu, A. R. S.; Raghunathan, R.; Baskaran, S. Tetrahedron 2009, 65, 2239; (c)
Smet, M.; Oosterwijck, C. V.; Hecke, K. V.; Meervelt, L. V.; Vandendriessche, A.;
Dehaen, W. Synlett 2004, 2388; (d) Cravotto, G.; Giovenzana, G. B.; Pilati, T.;
Sisti, M.; Palmisano, G. J. Org. Chem. 2001, 66, 8447.
Table 4
Synthesis of spiro-oxindoles having spiropiperidine rings 15a–h
Entry (14a–h)
R
R1
Product (15)a Time (min) Yieldb (%)
1
2
3
4
5
6
7
8
14a
14b
14c
14d
14e
14f
H
H
H
H
H
Cl
Br
15a
15b
15c
85
85
85
95
95
95
95
95
75
78
78
78
76
75
72
72
Methyl 15d
Allyl
Benzyl
Propargyl
Methyl
H
H
H
H
15e
15f
5. Kumar, R. S.; Perumal, S. Tetrahedron Lett. 2007, 48, 7164.
6. Alizadeh, A.; Mokhtari, J. Tetrahedron 2011, 67, 3519.
14g
14h
15g
15h
7. (a) Lakshmi, N. V.; Thirumurugan, P.; Perumal, P. T. Tetrahedron Lett. 2010, 51,
1064; (b) Lakshmi, N. V.; Thirumurugan, P.; Perumal, P. T. Synlett 2010, 955; (c)
Babu, T. H.; Joseph, A. A.; Muralidharan, D.; Perumal, P. T. Tetrahedron Lett.
2010, 51, 994; (d) Babu, T. H.; Karthik, K.; Perumal, P. T. Synlett 2010, 1128.
8. Lakshmi, N. V.; Arun, Y.; Perumal, P. T. Tetrahedron Lett. 2011, 52, 3437.
9. Shestopalov, A. M.; Emeliyanova, Y. M.; Shestopalov, A. A.; Rodinovskaya, L. A.;
Niazimbetova, Z. I.; Evans, D. H. Tetrahedron 2003, 59, 7491.
a
The products were characterized by spectral and elemental analysis.
Isolated yield by recrystallization.
b
series of spiropiperidine derivatives. Moreover a further delinea-
tion to replace isatin by isatylidene malononitrile as Michael
acceptor to synthesize spiro-oxindoles containing spiro piperidine
rings is also discussed. The simplicity of the approach makes this
strategy useful for the synthesis of novel spiro frameworks. Further
studies to delineate the scope and limitations of the present meth-
odology are underway.
10. Spectral data of compound 3: 1H NMR (500 MHz, DMSO-d6): d 1.46–1.49 (m,
1H), 1.61–1.64 (m, 1H), 2.00 (s, 3H, -NCH3), 2.11–2.12 (m, 3H), 2.14–2.16 (m,
1H), 2,2 (s, 3H, -NCH3), 2.42–2.44 (m, 1H), 2.66–2.68 (m, 2H), 2.77 (d, 1H,
J = 7.0 Hz), 2.92–2.95 (m, 1H), 3.10–3.12 (m, 1H), 3.19–3.21 (m, 1H), 5.68 (t, 1H,
J = 2.5 Hz), 7.27 (s, 2H, –NH2, D2O exchangeable). 13C NMR (125 MHz, DMSO-
d6): 26.6, 33.2, 43.8, 45.7, 46.1, 50.9, 51.8, 53.1, 53.3, 54.6, 55.3, 81.0, 113.2,
113.3, 116.1, 120.2, 126.7, 142.9. MS (EI): (m/z) 323.12 [M+H]+.
11. Typical experimental procedure for 5a: A mixture of N-methyl-4-piperidone 1
(1.0 mmol), malononitrile 2 (1.0 mmol) in the presence of triethyl amine was
refluxed in ethanol for 5 min. After that, isatin 4a (1.0 mmol) was added and
was refluxed for 40 min and cooled to room temperature. The solid formed in
the reaction mixture was filtered and dried under vacuum. The crude solid
product was purified by recrystallization in ethanol to obtain the pure product
5a in good yield (85%).
Acknowledgment
One of the authors, N.V. thanks the Council of Scientific and
Industrial Research (CSIR), New Delhi, India for the research
fellowship.
12. Spectral data of compound 5a (Table 1, entry 1): White solid. mp 284–286 °C. Rf
0.25 (50% EtOAc/Petroleum ether); mmax (KBr): 3449, 3314, 2943, 2797, 2249,
1742, 1635, 1583, 1471, 1323, 1211, 1123, 1082, 791, 749 cmÀ1 1H NMR
.
(500 MHz, DMSO-d6): d 1.14 (t, 1H, J = 10.7 Hz), 1.61 (t, 1H, J = 11.45 Hz), 1.86–
1.89 (m, 2H), 1.94–1.96 (m, 1H), 2.02–2.04 (m, 1H), 2.13 (s, 3H, –NCH3), 2.17 (s,
3H, –NCH3), 2.50–2.52 (m, 1H), 2.69–2.72 (m, 2H), 2.81–2.83 (m, 1H), 3.07–
3.09 (m, 1H), 3.31–3.33 (m, 2H), 6.77 (d, 1H, J = 7.65 Hz, Ar-H), 6.90–6.93 (m,
2H, Ar-H), 7.29 (t, 1H, J = 7.65 Hz, Ar-H), 8.29 (s, 2H, –NH2, D2O exchangeable),
9.07 (br s, 1H, –NH, D2O exchangeable), 10.02 (br s, 1H, –NH, D2O
exchangeable). 13C NMR (125 MHz, DMSO-d6): 31.2, 31.9, 37.9, 43.7, 45.6,
46.0, 51.3, 52.7, 55.3, 58.3, 81.2, 81.3, 111.2, 114.0, 119.4, 122.9, 123.2, 124.9,
125.6, 131.7, 142.7, 160.0, 172.6. MS (EI): (m/z) 470.20 [M+H]+. Anal. Calcd for
Supplementary data
Supplementary data associated with this article can be found, in
References and notes
C
26H27N7O2: C 66.51; H 5.80; N 20.88. Found: C 66.54; H 5.78; N 20.93.
13. Crystallographic data for compound 5a in this paper have been deposited with
the Cambridge Crystallographic Data centre as supplemental publication no.
CCDC-833093. Copies of the data can be obtained, free of charge on application
to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (Fax: +44 01223 336033 or
email: deposit@ccdc.cam.ac.uk).
1. Dimmock, J. R.; Jha, A.; Zello, G. A.; Sharma, R. K.; Shrivastav, A.; Selvakumar, P.;
Allen, T. M.; Santos, C. L.; Balzarini, J.; De Clercq, E.; Manavathu, E. K.; Stables, J.
P. J. Enzyme Inhib. Med. Chem. 2003, 18, 325.
2. Dandia, A.; Gautam, S.; Jain, A. K. J. Fluorine Chem. 2007, 128, 1454.